Captor Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Captor Therapeutics's estimated annual revenue is currently $8.3M per year.
- Captor Therapeutics's estimated revenue per employee is $77,500
Employee Data
- Captor Therapeutics has 107 Employees.
- Captor Therapeutics grew their employee count by 1% last year.
Captor Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $13.7M | 177 | -12% | N/A | N/A |
#2 | $12.1M | 156 | 21% | N/A | N/A |
#3 | $10.7M | 138 | 8% | N/A | N/A |
#4 | $0.3M | 4 | -20% | N/A | N/A |
#5 | $100.7M | 1299 | 10% | N/A | N/A |
#6 | $8.3M | 107 | 1% | N/A | N/A |
#7 | $8.5M | 110 | 8% | N/A | N/A |
#8 | $104.3M | 841 | 3% | N/A | N/A |
#9 | $5.6M | 72 | 33% | N/A | N/A |
#10 | $8.7M | 112 | 38% | N/A | N/A |
What Is Captor Therapeutics?
Captor Therapeutics is a high-tech pharmaceutical company focused on targeting the undruggable proteome. Our mission is to transform lives of patients suffering from cancer, viral infections, and inflammatory and neurodegenerative diseases. Our groundbreaking technology is perfectly suited to ease patients'​ burden and cure conditions that so far have only been poorly treatable.​ Our company is a pioneer of a small molecule-induced targeted degradation of proteins with particular expertise covering degradation of membrane proteins. We are privately held start-up with total of 65+ years of experience in pharmaceutical industry. We collaborate closely with renowned biology and chemistry experts from top American and European academic institutions.
keywords:N/A
N/A
Total Funding
107
Number of Employees
$8.3M
Revenue (est)
1%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Captor Therapeutics News
Australia's Chimeric Therapeutics has partnered with WuXi ATU, a global ... Captor Therapeutics: Based in Poland, Captor announced the...
Captor Therapeutics is a biopharmaceutical company focused on leveraging Targeted Protein Degradation (TPD) technology to discover and develop...
Dr. Tom Shepherd, Chief Executive Officer of Captor Therapeutics, will participate in an expert panel discussion focused on Targeted Protein...
TOKYO and CAMBRIDGE, England, Dec. 22, 2020 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565), a world leader in GPCR-focused structure-based drug design and development, and Captor Therapeutics SA ("Captor"; Wroclaw, Poland and Allschwil, Switzerland), a European leader in tar ...
TOKYO and CAMBRIDGE, England, Dec. 22, 2020 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565), a world leader in GPCR-focused structure-based drug design and development, and Captor Therapeutics SA ("Captor"; Wroclaw, Poland and Allschwil, Switzerland), a European leader in tar ...
Other Companies in Wrocław
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $8.6M | 119 | 25% | N/A |
#2 | $8.9M | 123 | -34% | N/A |
#3 | $11.2M | 140 | 5% | N/A |
#4 | $17.2M | 208 | 40% | N/A |
#5 | $17.1M | 222 | 1% | N/A |